Exelixis Expands 2021 Clinical Trial Collaboration and Supply Agreement with BMS for XL092 as Fixed Dose Combination in P-Ib (STELLAR-002) Trial for Advanced Solid Tumors
Shots:
- The companies collaborated for the P-Ib (STELLAR-002) dose-escalation & cohort-expansion study evaluating the safety, tolerability, PK, preliminary antitumor activity & effect of biomarkers of XL092 as monothx. and in combination with nivolumab (doublet) & nivolumab + ipilimumab (triplet) in 622 patients with advanced solid tumors. In the dose-escalation portion of the trial, patient enrollment and dosing are ongoing
- Exelixis will be a sponsor of the trial. BMS will provide the fixed-dose combination of nivolumab and relatlimab along with nivolumab and ipilimumab
- The dose-escalation stage will determine the recommended dose for advanced solid tumors for each of the combination therapy regimens
Ref: Exelixis | Image: Exelixis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
